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Abstract
Background: Inflammation represents an early and key event in the development of both the cutaneous psoriasis and
psoriatic arthritis. Compelling evidences indicate that the production of TNF-α plays a central role in psoriasis by
sustaining the inflammatory process in the skin as well as in the joints. Among the multiple effects produced by TNF-α
on keratinocytes, the induction of matrix metalloproteinase-9 (MMP-9), a collagenase implicated in joint inflammatory
arthritis which acts as an angiogenesis promoting factor, might represent a key mechanism in the pathogenesis of the
disease. Aims of the present study were to investigate a) the role of MMP-9 in the development of psoriasis by assessing
the presence of MMP-9 in lesional skin and in sera of psoriatic patients; b) the association of MMP-9 with the activity of
the disease; c) the relationship between MMP-9 and TNF-α production.
Methods: Eleven psoriatic patients, clinically presenting joint symptoms associated to the cutaneous disease, were
included in a therapeutic protocol based on the administration of anti-TNF-α monoclonal antibody (Infliximab). Sera and
skin biopsies were collected before treatment and after 6 weeks of therapy. Tissues were kept in short term cultures
and production soluble mediators such as TNF-α, MMP-9, MMP-2, VEGF and E-Selectin, which include angiogenic
molecules associated to the development of plaque psoriasis, were measured in the culture supernatants by
immunoenzymatic assays (ng/ml or pg/ml per mg of tissue). MMP-9 concentrations were also measured in the sera. The
cutaneous activity of disease was evaluated by the Psoriasis Area and Severity Index (PASI).
Results: Clinical and laboratory assessment indicated that all but one patients had a significant improvement of the PASI
score after three months of therapy. The clinical amelioration was associated to a significant decrease of MMP-9 (P =
0.017), TNF-α (P = 0.005) and E-selectin (P = 0.018) levels, spontaneously released by lesional biopsies before and after
therapy. In addition, significant correlations were found between the PASI measurements and TNF-α (r2 = 0.33, P =
0.005), MMP-9 (r2 = 0.25, P = 0.017), E-selectin (r2 = 0.24, P = 0.018) production. MMP-9 levels were significantly
correlated with those of TNF-α (r2 = 0.30, P = 0.008). A significant decrease of MMP-9 in the sera, associated to the
clinical improvement was also found.
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Conclusion: Our findings show the existence of a direct relationship between MMP-9 and TNF-α production strongly
suggesting that MMP-9 may play a key role in the skin inflammatory process in psoriasis.
Background
Psoriasis is a chronic inflammatory skin disease character-
ized by hyperproliferation of epidermal cells with promi-
nent blood vessels and a thick perivascular lymphocytic
infiltrate [1]. The etiology of psoriasis is still unknown.
Whether the disease results from a primary abnormality in
epidermal keratinocytes or depends upon a deregulation
of the immune system it has been matter of controversial
debating [2]. Recent evidence, however, indicated that
activated lymphocytes and keratinocytes are both
required for the development of psoriatic lesion [3]. In
fact, the chronic, self-aggressive, epidermal T cells activa-
tion, characteristic of the disease, might be initiated by
common streptococcal infections (β-haemolitic strepto-
cocci) that, in turn, might trigger a cross immune recogni-
tion between streptococcal M proteins and those keratins
that are pathologically up-regulated in psoriatic lesions
[4]. An auto-immune response may thus be sustained by
a mechanism of molecular mimicry. Indeed, psoriatic
keratinocytes exhibit an altered phenotype characterized
by a costitutive Stat3 activation [3] and a different
response to IFN-γ compared to normal keratinocytes
[5,6].
About one third of patients with psoriasis also suffer of an
inflammatory arthritis with clinical and biological fea-
tures that are partially similar to rheumatoid arthritis (RA)
[7]. Although, the systematic classification and the diag-
nostic criteria for this form of arthritis are still under vali-
dation [8], psoriatic arthritis (PsA) has been recognized as
a clinical entity distinct from RA, due to the absence of the
rheumatoid factor as well to the presence of specific clini-
cal features. Articular erosions in PsA occurr less com-
monly than in RA and progression to joint destruction
occurs at a slower rate, nevertheless it can lead to disability
[9].
Compelling evidences indicate that TNF-α plays a central
role in sustaining the psoriatic inflammatory process in
skin as well as in joints [9,10]. In psoriatic skin, TNF-α is
the prevalent cytokine: it can be produced by several cell
types including activated T cells, keratinocytes, macro-
phages and Langerhans cells [11]. Moreover, in epidermal
keratinocytes, TNF-α regulates genes involved in immune
and inflammatory response, including those involved in
cell motility or cytoskeleton changes or in extracellular
matrix remodelling [12]. In the affected joints TNF-α
appears as well responsible of the positive regulation and
overexpression of chemokines, cytokines and angiogenic
molecules which may lead to proliferation and activation
of sinovial cells that, in turn, lead to cartilage and bone
destruction [13]. Moreover TNF-α has been implicated in
promoting osteoclastogenesis in PsA [14].
Therapeutic approaches based on anti-TNF-α agents have
provided indirect evidence in support to this hypothesis,
since they are highly effective in controlling both skin and
joint manifestations in patients with PsA [15,16]. We have
recently demonstrated that the marked improvement in
both skin and joint manifestations following therapy with
Infliximab, a chimeric monoclonal antibody which binds
specifically to human TNF-α [17], was significantly asso-
ciated to the decrease of serum levels of TNF-α, angiogenic
molecules and MMP-2 [18]. MMPs belong to a family of
proteolytic enzymes that are capable of degrading all com-
ponents of the extracellular matrix, a key event in the
development of cartilage destruction and joint erosion
[19]. Kinetic studies using known model substrates have
shown that both MMP2 and MMP9 are most effective in
degrading collagen as compared to other MMPs [20] and
have been specifically implicated in inflammatory arthri-
tis, including angiogenesis [21-23]. In a recent paper we
described significant decreases of IL-6, VEGF, FGF-b and
E-selectin after early infliximab infusions and the signifi-
cant correlations between PASI and MMP-2, FGF-b or
VEGF [18].
In the present study we investigated the modifications of
TNF-α, MMP-9 and MMP-2 released by the cellular ele-
ments located in the skin lesional tissue of patients with
PsA, during treatment with Infliximab. We also deter-
mined the amounts of endothelial activation VEGF and E-
selectin molecules, which are significantly associated to
disease activity in psoriasis plaques [24,25]. MMP-9 levels
were also determined in the sera.
The results showed a significant decrease of lesional
amounts of MMP-2, MMP-9, TNF-α and E-selectin, in
association with the clinical improvement of disease
symptoms, occurring after three weeks of Infliximab mon-
otherapy. A significant correlation was found also
between peripheral levels of MMP-9 and PASI, differently
from what previously found analysing MMP-2 serum lev-
els [18].
Patients and methods
Patients
Eleven patients (9 males, 2 females) aged 35–60 years
with a clinical diagnosis of PsA were included in the study
upon releasing of a written informed consent. They wereJournal of Autoimmune Diseases 2006, 3:5 http://www.jautoimdis.com/content/3/1/5
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part of a larger group of patients partecipating to a mono-
therapy therapeutic protocol based on Infliximab admin-
istration. The study protocol was approved by the
Hospital Ethics Committee. The design of the study and
the enrollement criteria have already been described [18].
Briefly, Infliximab (5 mg/kg) was administered by intrave-
nous infusion at week 0 and at weeks 2 and 6, and subse-
quently every 12 weeks. Disease activity was monitored at
baseline, and before each programmed infusion. Skin
involvement was evaluated with Psoriasis Area and Sever-
ity Index (PASI) [26]. Arthritis was evaluated following
the American College of Rheumatology criteria (ACR)
[27] with clinical examination of the tender and swollen
joints, laboratory tests of inflammatory markers (erythro-
cyte sedimentation rate = ESR and C-reactive protein =
CRP) and radiological examination of joint damage. An
effective response to therapy was classified on the basis of
improvement of PASI and/or ACR greater than 50% in
comparison with baseline values.
Short-term organ cultures
Lesional tissue specimens (4 mm punch biopsies) were
taken at the enrollement visit and at week 6, before the
third drug infusion, in the same skin area. Each tissue
sample was rinced in cold sterile medium, weighed after
removing fluid excess, and kept in short term culture in a
polypropilene tube with 1 ml of complete medium (RPMI
1640, 10% FCS, 2 mM L-glutamine, antibiotics) in a 5%
CO2 atmosphere at 37°C. After 36 hrs of incubation, the
supernatant was collected, spinned in a cold microcentri-
fuge at 1000 × g and subdivided in small aliquots to be
stored frozen at -80°C, until testing. After culture, biop-
sies were frozen and cryostatic tissue sections were exam-
ined: the structure of the skin was well preserved and
included the dermis up to the reticular region.
Sera
Blood samples were collected before drug infusion at
week 0 and week 6. Sera were stored frozen in small aliq-
uots for cytokine assays.
Cytokine assays
The amounts of different biological mediators (TNF-α,
VEGF, E-selectin, MMP-2, MMP-9) released in culture
supernatants from the lesional tissue samples were meas-
ured by quantitative enzyme immunoassays (Quantikine
Immunoassays, R&D Systems, Minneapolis, MN, USA),
following the manufacturer's instructions. Samples and
standards were analyzed in duplicate. Results were
expressed as pg/ml or ng/ml per milligram of tissue. The
sensitivity of each assay, according to the manufacturer,
are reported in Table 1. MMP-9 amounts were addition-
ally measured in the sera of patients collected concomi-
tantly to skin biopsies.
Statistical analysis
Cytokine measurements released before treatment were
compared with those determined after therapy, by the
paired t test, for the group of variables showed a normal
distribution by the Kolmogorov-Smirnov (KS) test. Differ-
ences were considered significant when a two tailed P <
0.05 was obtained. The correlation between the PASI
scores and the lesional levels of cytokines and MMPs and
was evaluated by the Pearson correlation coefficient r2 and
two-tailed P value. Statistical analysis was performed by
using the Graph Pad Software Prism 4 (GraphPad Soft-
ware Inc., San Diego, CA).
Results and discussion
Clinical evaluation
Biological therapy based on monoclonal antibodies
against TNF-α has been proven to be effective in patients
with psoriatic arthritis on both the arthropaty and the
cutaneous symptoms of the disease [15,16,28]. Today
there are three main biological agents targeting TNF-α,
which are already in use for treating PsA. These are the chi-
meric monoclonal IgG1 antibody infliximab with human
constant and murine variable regions, the fully human
anti-TN F-α monoclonal antibody adalimumab and the
recombinant 75-kDa TNF receptor IgG1 fusion protein
etanercept [29]. All catch soluble TNF-α in the plasma,
only etanercept also bind to TNF-β. Infliximab and adali-
mumab also bind to cell membrane bound TNF-α, which
may lead to cell lysis. There are several reports on the effi-
Table 1: Improvement of psoriasis cutaneous expression after therapyand MMPs or cytokine levels released in tissue culture 
supernantans
Baseline values After 6 weeks Paired t P
PASI score 19.1 ± 7.8 7.4 ± 2.7 0.0002
TNF-α *(pg/ml) **0.12 294.7 ± 123.5 194.9 ± 67.8 0.02
MMP-9 *(ng/ml) **0.15 207.3 ± 240.6 43.3 ± 73.9 0.03
MMP-2 *(ng/ml) **0.16 1404.0 ± 1081.0 1205.0 ± 1142.0 0.048
VEGF *(pg/ml) **9.0 510.7 ± 376.6 240.6 ± 270.1 0.02
E-Selectin *(ng/ml) **0.1 18.9 ± 23.5 4.1 ± 3.3 0.05
*Data are normalized per mg of tissue – **minimum detectable dose according to the manufacturerJournal of Autoimmune Diseases 2006, 3:5 http://www.jautoimdis.com/content/3/1/5
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cacy of infliximab in PsA [16,18]. Recent data from large
placebo-controlled studies have shown that the medica-
tion is highly effective [30,31].
In the present study a group of patients with PsA, which
underwent a monotherapy with Infliximab, also showed
clinical improvements in skin and joint disease, as
referred in a previous study [18]. At week 6 the ACR
indexes showed a 50% improvement as compared to
baseline values (week 0) in all patients. The PASI score at
baseline ranged between 8.9 and 30.2, mean value: 19.06
± 7.78; at week 6, it ranged between 4.5 and 12.3, mean
value: 7.4 ± 2.68 (P = 0.0002). Ten patients showed an
improvement >= 50% of the skin lesions (mean value of
PASI improvement: 62.65 % ± 8.95 SD). One patient,
with mild skin disease (baseline PASI score = 10.1), did
not show a significant improvement after 6 weeks (PASI
score = 10.0). Data are described in detail in Table 1.
Cytokine levels
In the present study we found that the clinical improve-
ment of the skin expression of the disease in patients with
psoriatic arthritis under Infliximab significantly correlated
with the decrease of lesional MMP-9 in association with
the decrease of TNF-α, or VEGF and E-selectin, bioactive
molecules already known to be implicated in the patho-
genesis and clinical activity of the disease [32]. The
approach used in the present study to measure the
lesional levels of soluble molecules has been already
adopted in previous studies demonstrative of the presence
of inflammatory cytokines in psoriatic lesional tissue in
comparison to uninvolved as well as normal skin samples
[33,34].
By using this methodology, the mean values of TNF-α,
VEGF, E-selectin, MMP-2 and MMP-9 released by lesional
tissues before or after therapy have been measured and the
results are summarized in Table 1. A significant decrease
of all molecules was found after therapy. To establish a
quantifiable relationship between the severity of cutane-
ous disease expression and the lesional levels of TNF-α,
VEGF, E-selectin, MMP-2 or MMP-9, the correlation coef-
ficients of each cytokine and the PASI score, taken at the
same time as the corresponding of lesional biopsy, were
calculated by the Pearson correlation test. The diagram in
Fig. 1 depicts the plotted results of correlation and linear
regression analysis. A statistically significant correlation
was found between the PASI score and TNF-α, MMP-9 or
E-selectin concentrations. Expression of TNF-α and MMP-
9 were also significantly correlated.
TNF-α is considered a key cytokine regulator in psoriasis
[35]. As expected, the lesional amounts of TNF-α were
directly correlated with the PASI score, sustaining its path-
ogenic role in the development of skin psoriasis. The cor-
relation found between MMP-9 and PASI, suggests that
also this molecule may be involved in the inflammatory
process leading to the cutaneous lesions. Indeed, TNF-α
acts as a potent inducer of MMP-9 in keratinocytes [12].
Therefore, TNF-α mediated induction of MMP-9 could be
responsible of the overexpression and activity of this mol-
ecule as found in the synovial cells and skin of patients
with PsA [36-38,22]. On the other hand, MMP-9 can be
also secreted by inflammatory cells, such as neutrophils,
upon activation by the IL-8 family proteins [39]. Moreo-
ver, MMP-9 mediates terminal cleavage of IL-8, thus
potentiating IL-8-induced activation of neutrophils [40].
This suggest that MMP-9 can be involved as a mediator of
the IL-8-induced inflammatory process in the psoriatic
skin [41]. The use of supernatants from short-term cul-
tured punch biopsies cannot allow to define the target
cells producing MMP-9. However, recent data obtained by
immunohistochemical analysis of psoriatic skin and syn-
ovia in individuals under infliximab treatment showed
that the drug decreased the neoangiogenesis and reduced
the activation of the endothelial cells resulting in
decreased cell infiltration and clinical improvement [42].
Differently from that found in the sera [18], MMP-2
amounts in the skin lesions were scarcely modified by Inf-
liximab monotherapy (P = 0.048), while MMP-9 lesional
and serum levels were both strongly reduced. MMP-9 lev-
els found in the sera collected before the third drug infu-
sion were significantly reduced as compared to baseline
values (Fig. 2a). Moreover, serum MMP-9 and TNF-α lev-
els were significantly correlated as shown in the plot
depicted in of Fig. 2b, referring to cumulative measures.
Although the correlation coefficient values are low, the
statistical significance in complex primary culture model
system such as the skin and in the relatively small-sized
population sample studied here suggest that the observed
correlations might be of biological importance.
This finding might suggest that MMP-2, a type IV colla-
genase secreted by fibroblasts, is mainly involved in joint
lesions of PsA, while MMP-9 contributes to the chronic
inflammatory process in the skin of the psoriatic patients
either directly, by sustaining the inflammatory process
and the tissue distruction or indirectly, by allowing the
traffic of inflammatory cells and enhancing the activity of
inflammatory cytokines. In fact, experimental evidences
indicate that MMPs can mediate the proteolytic process
leading to the release of the soluble, active molecule of
TNF-α from a cell membrane-achored molecular form
[43]. In addition, due to its proteolytic activity, MMP-9
could contribute to the generation of immunogenic frag-
ments of normal proteins that may offer the basis for the
initiation of local autoimmune cellular responses.Journal of Autoimmune Diseases 2006, 3:5 http://www.jautoimdis.com/content/3/1/5
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Correlation plots and linear regression lines between cutaneous expression of disease (PASI score) and TNF-α, MMP-9, VEGF,  MMP-2, E-selectin amounts released by lesional tissue in short term cultures Figure 1
Correlation plots and linear regression lines between cutaneous expression of disease (PASI score) and TNF-α, MMP-9, VEGF, 
MMP-2, E-selectin amounts released by lesional tissue in short term cultures. The correlation and linear regression curve 
between TNF-α and MMP-9 is also shown.Journal of Autoimmune Diseases 2006, 3:5 http://www.jautoimdis.com/content/3/1/5
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The inhibitory effect of anti- TNF-α therapy may thus offer
a two-fold efficacy through the reduction of MMP-9 levels
and the inhibition of processing of TNF-α precursor into
its active molecular form.
A knowledge of the fine mechanism regulating soluble
factors such as the MMPs, which also have a key role in tis-
sue repair [44], can help understanding the pathogenic
mechanisms underlying the generation of psoriatic
lesions and may thus have important therapeutic implica-
tions representing a powerful tool with which to direct
new therapeutic strategies.
Abbreviations
PsA: Psoriatic Arthritis
RA: Rheumatoid Arthritis
MMPs: Matrix Metalloproteinases
PASI : Psoriasis Area and Severity Index
TNF-α : Tumor Necrosis Factor-α
VEGF: Vascular Endothelial Growth Factor
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